High Throughput Screening (HTS) Market Report 2026

The high throughput screening (hts) market size has grown strongly in recent years. It will grow from $25.26 billion in 2025 to $27.47 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to increasing demand for rapid drug discovery, advancements in assay technologies, growth in pharmaceutical R&D investments, rising adoption of robotics in laboratories, expansion of contract research organizations.

The high throughput screening (hts) market size is expected to see strong growth in the next few years. It will grow to $38.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to integration of ai and machine learning in hts, growth of personalized medicine, rising investments in biotechnology startups, expansion of emerging markets in asia-pacific, development of multiplexed and label-free assay technologies. Major trends in the forecast period include high-throughput automation integration, miniaturization of screening platforms, advanced detection technologies, multiplexed assay development, cloud-based data management.

The increasing prevalence of chronic diseases is expected to drive the growth of the high-throughput screening (HTS) market in the coming years. Chronic disease refers to a long-term health condition that persists over an extended period, typically lasting three months or more. HTS allows rapid screening of numerous chemical compounds to identify potential drug candidates targeting specific pathways or mechanisms involved in chronic diseases, which is essential for their effective long-term management. For instance, in January 2023, the National Library of Medicine, a US-based government agency, reported that the number of people in the US aged 50 and older with at least one chronic condition is projected to reach 142.66 million by 2050. Therefore, the rising prevalence of chronic diseases is propelling growth in the high-throughput screening (HTS) market.

Major companies in the high-throughput screening market are developing innovative products, such as multimode plate readers, to provide advanced features and better support to researchers. A multimode plate reader (MPR) is a sophisticated laboratory tool used in HTS, analyzing biological and chemical samples in microplates by combining multiple detection modes for various assays within a single platform. For instance, in February 2023, PerkinElmer Inc., a US-based MedTech company, launched the EnVision Nexus system. The EnVision Nexus system is recognized as the fastest and most sensitive multimode plate reader available, specifically designed for demanding high-throughput screening applications to accelerate drug discovery. With unique technologies including dual detectors and optimized reagents like proprietary HTRF and AlphaLISA, along with the latest reagent kits, the platform delivers exceptional assay flexibility, accuracy, speed, and sensitivity. Equipped with walkaway convenience options such as a plate stacker for 20 or 50 plates or full automation and integration for continuous 24/7 operations, the EnVision Nexus system enables researchers to screen millions of samples efficiently.

In December 2023, PerkinElmer Inc., a US-based MedTech company, acquired Covaris Inc. for an undisclosed amount. This acquisition is expected to accelerate Covaris’ growth potential while expanding PerkinElmer’s existing life sciences portfolio into the rapidly growing diagnostics market. Covaris Inc. is a US-based provider of high-throughput screening solutions.

Major companies operating in the high throughput screening (hts) market are Thermo Fisher Scientific Inc., AstraZeneca Plc, Danaher Corporation, Merck Group, GE HealthCare Technologies Inc., Corning Inc., Agilent Technologies Inc., Lonza Group Ltd., Charles River Laboratories International Inc, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories, Tecan Group Ltd., Sygnature Discovery Ltd., Luminex Corporation, Hamilton Company, Crown Bioscience Inc., HighRes Biosolutions, NanoTemper Technologies GmbH, BMG LABTECH GmbH, Axxam SpA, Reprocell Inc., BioTek Instruments Inc, Aurora Biomed Inc., Cyclica Inc.

North America was the largest region in the high throughput screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (hts) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the high throughput screening (hts) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the high-throughput screening market by increasing the cost of importing critical instruments, consumables, and software from major manufacturing hubs such as China and the US. These tariffs have created supply chain challenges, particularly impacting automated liquid handlers, robotics, and assay kits. While pharmaceutical and biotechnology companies in regions like North America and Europe face higher procurement costs, some local manufacturers benefit from increased demand for domestically produced HTS components. Overall, tariffs are prompting companies to diversify sourcing strategies, invest in regional manufacturing, and optimize operational efficiency.

The high throughput screening (hts) market research report is one of a series of new reports that provides high throughput screening (hts) market statistics, including high throughput screening (hts) industry global market size, regional shares, competitors with a high throughput screening (hts) market share, detailed high throughput screening (hts) market segments, market trends and opportunities, and any further data you may need to thrive in the high throughput screening (hts) industry. This high throughput screening (hts) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

High-throughput screening (HTS) is a technique used in drug discovery and other scientific fields to quickly evaluate a large number of samples for biological activity. Its goal is to identify active compounds, antibodies, or genes that influence specific biological pathways, thereby accelerating the drug discovery process.

The main types of products and services in high-throughput screening (HTS) include consumables and reagents, instruments, software, and services. Consumables and reagents are the materials and chemicals used in the screening process, such as sample containers, assay reagents, and other disposable items needed for experiments. The technology types include ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technologies, which are applied in areas such as target identification and validation, primary and secondary screening, toxicology assessment, and others. End users include the pharmaceutical and biotechnology industries, academic and research institutes, contract research organizations, and others.

The high-throughput screening (HTS) market consists of revenues earned by entities by providing services such as compound library screening, assay design and adaptation, and pilot screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The high-throughput screening (HTS) market also includes sales of lab equipment and supplies, chemicals, assay development tools, and data processing software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.